Physician profile
Byron Flores
NPI 1881601383
$1,582.99
in general payments reported to CMS, 2019-2025
16 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $143 · 2021: $22.69 · 2022: $74.27 · 2023: $189 · 2024: $633 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $338.91 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $226.03 | 2023-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Abbvie INC. | $125.00 | 2020 | |
| Amag Pharmaceuticals, INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $109.42 | 2024 | Farxiga |
| Cranial Technologies, INC | $104.83 | 2024-2025 | Doc Band |
| Glaxosmithkline, LLC. | $97.41 | 2022-2024 | Bexsero, Rotarix, Pediarix |
| Pfizer INC. | $85.70 | 2021-2024 | |
| Novo Nordisk INC | $84.73 | 2023-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $71.67 | 2024 | |
| Novartis Pharmaceuticals Corporation | $52.10 | 2019 | |
| Amgen INC. | $48.10 | 2023 | Otezla, Repatha |
| Dexcom, INC. | $40.57 | 2023-2024 | Dexcom G6 Transmitter |
| Merz North America, INC. | $31.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.32 | 2024 | Xarelto |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $18.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.